JPRN-UMIN000011440已完成2 期
Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer - JACCRO CC-09 study
onprofit Organization Japan Clinical Cancer Research Organization0 个研究点目标入组 35 人开始时间: 2013年8月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Synchronous multiple maligmancy or metachronous multiple malignancy within 5 years disease free interval (2) Symptomatic brain metastases (3) Severe infectious disease (4) Comorbidity or history of interstitial lung disease or pulmonary fibrosis (5) Comorbidity or history of severe heart disease (6) Sensory alteration or paresthesia interfering with function (7) Large quantity of pleural, abdominal or cardiac effusion (8) Severe comobidity (renal failure, liver failure, hypertensio, etc) (9) Prio radiotherapy for primary and metastatic tumor (10) Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (11) Any other cases who are regarded as inadequate for study enrillment by investigators
研究者
相似试验
进行中（未招募）
不适用
An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer.Ensayo Clínico fase II de Panitumumab combinado con quimioterapia de Irinotecan como tratamiento de segunda linea en sujetos con cáncer colorectal metastásico.EUCTR2006-006363-24-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)80
进行中（未招募）
不适用
A Phase II Clinical Trial of Panitumumab in Combination with Infusional Oxaliplatin and Oral Capecitabine (XELOX) Chemotherapy as 1st line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases - NDPreviously untreated Patients with Colorectal Cancer and Advanced Liver Metastases.MedDRA version: 9.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-002007-41-ITAZIENDA OSPEDALIERA ORDINE MAURIZIANO
进行中（未招募）
不适用
Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junctioAdenocarcinoma of the stomach or the gastroesophageal junctionMedDRA version: 14.1Level: LLTClassification code 10017768Term: Gastric cancer stage IV without metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10017767Term: Gastric cancer stage IV with metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018993-20-DEniversitätsklinikum Schleswig-Holstein, Campus Kiel
进行中（未招募）
不适用
Estudio clínico abierto de fase II de panitumumab en combinación con quimioterapiaFOLFIRI como tratamiento de segunda línea en sujetos con cáncer colorrectalmetastásico que expresa KRAS no mutado y que haya progresado ≥ 6 meses despuésde la última dosis de la quimioterapia de primera línea - ACTIVECáncer colorrectal metastásico que expresa KRAS no mutadoEUCTR2009-010975-26-ESAssociació Catalana per a la Recerca Oncológica i les seves implicacions Sanitáries i Socials
进行中（未招募）
1 期
Anti - EGFR therapy rechallenge in combination with chemotherapy in patients with advanced colorectal cancer.RAS wild type advanced colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003644-37-GRHellenic Cooperative Oncology Group (HeCOG)33